BIOlogics in Severe Nasal POlyposis SurvEy.: a French Registry

Launched by UNIVERSITY HOSPITAL, LILLE · Jul 9, 2024

Keywords

ClinConnect Summary

This clinical trial, called the BIOlogics in Severe Nasal POlyposis SurvEy, is focused on understanding how new biologic treatments can help people with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). This condition affects about 2-4% of people in Western countries and can significantly lower the quality of life. The trial aims to monitor patients who are starting biologic treatments to see how these therapies improve their symptoms, overall well-being, and how well they tolerate the treatments.

To be eligible for the trial, participants must be over 18 years old and need a biologic treatment for their CRSwNP, following specific guidelines. Those who have received certain prior treatments in the last few months or have certain health conditions may not be able to participate. Throughout the study, patient experiences will be tracked, and researchers will collect information about their medical history and how they respond to the new treatments. This information will help doctors better understand how to treat CRSwNP in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients of over 18-year old requiring a biologic treatment for CRswNP in accordance with its marketing approval.
• • The patients already treated according to this criteria since August 2021 will be followed and their previous clinical and biological data retrospectively collected
• Exclusion Criteria:
• • Oral corticotherapy in the previous month;
• • Biologic treatment with anti-IgE (omalizumab), anti-IL-5/IL-5R (mepolizumab, benralizumab) or anti-IL-4/IL-13R (dupilumab) or any other biotherapy for inflammatory diseases in the previous 6 months of initiation of treatment apart from ongoing biotherapies for severe asthma or CRSwNP;
• • Hypersensitivity to humanized antibodies ;
• • Documented SARS-Cov2 infection in the last 3 months with persistent olfactory disorders related to COVID;
• • Pregnant or breast-feeding women;
• • Patient without social coverage.